ABSTRACT
Objective To explore the clinical effect and safety of Shugan-Jianpi-Huayu decoction combined with entecavir for the patients with hepatic cirrhosis of hepatitis B.Methods A total of 150 patients with hepatic cirrhosis of hepatitis B visiting our hospital from Jan. 2013 to Jan. 2015 were enrolled and randomly divided into the observation group and control group, 75 in each group. The control group received entecavir, while the observation group received Shugan-Jianpi-Huayu decoction additionally. The index of liver fuction and liver fibrosis, clinical efficacy and adverse reactions were observed and compared after the treatment.Results After treatment, the AST (42.88 ± 12.57U/Lvs.56.94 ± 14.83U/L,t=6.263), ALT (41.10 ± 10.61U/L vs.53.12 ± 16.78U/L,t=5.243), TBIL (20.15 ± 9.76μmol/Lvs.28.35 ± 12.20μmol/L, t=4.545), PC Ⅲ (103.65 ± 22.84μg/Lvs. 162.44 ± 38.90μg/L,t=11.287),Ⅳ-C (106.72 ± 23.41μg/Lvs.152.94 ± 30.01μg/L, t=10.518), LN (92.75 ± 25.32μg/Lvs.156.64 ± 38.79μg/L,t=11.945), HA (105.58 ± 18.07μg/L vs.159.74 ± 35.50μg/L,t=11.775) of the observation group were significantly better than those of the control group (allP<0.05). The total efficacy rate of the observation group were 85.33% (64/75), which were significantly higher than 64.00% (48/75) of control group (χ2=9.023,P=0.003).Conclusions The Shugan-Jianpi-Huayu decoction combined with entecavir showed efficacy and safey for the patients with hepatic cirrhosis of hepatitis B.